Clinical Trial

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

Study acronym: REIMAGINEYOUNG
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the first part participant will get either CagriSema or placebo, and in the second part participant will get CagriSema. In the first part, which treatment participant gets is decided by chance and second part is open label and all participants will get CagriSema during this part. The study will last for about 1 year and 3 months.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-12-05; most recent amendment 2026-05-27.
Trial Details
NCT Number NCT07282613
Lead Sponsor Novo Nordisk A/S
Conditions Diabetes Mellitus, Type 2
Enrollment 80 participants
Start Date 2026-08-04
Primary Completion 2029-09-07 (estimated)
Study Completion 2030-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-28